Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
We conduct the phase II clinical trial to further explore the efficacy and safety of Apatinib
Mesylate in treating recurrent or metastatic esophageal squamous cell carcinoma after the
failure of conventional treatments. An exploratory molecular marker analysis will be
performed in order to find out the beneficial population of Apatinib Mesylate.